MSA with Global Pharmaceutical Company

CelLBxHealth PLC

29 May 2026

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

CelLBxHealth plc

 ("CelLBxHealth" or "the Company")

Master Services Agreement with Global Pharmaceutical Company

CTC-powered analytics for drug discovery and development

Guildford, UK and Plymouth Meeting, U.S. - 29 May 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that it has entered into a Master Services Agreement with AstraZeneca.

The agreement establishes CelLBxHealth as a qualified service provider to AstraZeneca, enabling the Company to support drug discovery and development through CTC powered analytics of clinical trial samples using the Parsortix® platform.

Peter Collins, Chief Executive Officer of CelLBxHealth, commented: "We are delighted to enter into this Master Services Agreement which enables AstraZeneca to access our capabilities across their development pipeline. We look forward to delivering strong and productive outcomes through this framework."

For further information:

CelLBxHealth plc Peter Collins, Chief Executive Officer Jan Groen, Executive Chairman	[e-mail] via Walbrook PR
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales)	[phone]
Walbrook PR (Investor and Media Relations) Paul McManus / Alice Woodings	Tel: [phone] or [e-mail] Mob: [phone]

Notes for editors 

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial focus spans three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.

For more information, visit https://cellbxhealth.com/.

 

END